Pierpaolo Padula

Autonome VR‑therapie die wachtlijsten verkort en resultaten versnelt De GGZ kampt met lange wachttijden. Psylaris maakt therapie direct schaalbaar met evidence‑based Virtual‑Reality‑modules. Onze oplossing Psylaris ontwikkelt autonome VR‑therapieën voor EMDR, Exposure en CGT. Cliënten volgen de sessies zelfstandig, thuis of in de praktijk, terwijl de therapeut in real‑time voortgangsdata ontvangt en de regie houdt. Het resultaat: tot 40 % minder behandelminuten per traject én snellere symptoomreductie. Bewezen impact: ● 850+ zorgorganisaties in NL, BE & DE ● 100 000+ VR‑sessies sinds 2021 ● Onafhankelijke studies met universiteiten en GGZ‑instellingen bevestigen onze effectiviteit Onze missie De druk op de GGZ verlichten zonder de menselijke maat te verliezen. Samen met behandelaren maken we zorg schaalbaar, persoonlijk en toekomstbestendig.

Carol è un servizio di virtual primary care in abbonamento, che permette di accedere a servizi sanitari digitali in modo facile e veloce, sempre e ovunque. Lapp comprende un ecosistema di servizi sanitari che offrono un’esperienza pratica, efficiente e totalmente digitale: teleconsulti di medicina generale via video e chat, prescrizione elettronica di ricette farmaceutiche e specialistiche; acquisto di farmaci con consegna a domicilio; prenotazione di visite specialistiche ed esami diagnostici nelle migliori strutture partner. Carol è il primo provider di servizi di telemedicina in Italia ad essere autorizzato dall’SSN come ambulatorio virtuale di medicina generale in regime privato. Un team di medici interno altamente qualificato e sempre reperibile garantisce una presenza dedicata ed il più elevato standard di qualità ai propri pazienti, supportato da una piattaforma tecnologica moderna.

Your hybrid clinic for gynecological health.

SeedLink SL enables innovative minds to advance the future of health and care. We provide funding, services and support.

Autonome VR‑therapie die wachtlijsten verkort en resultaten versnelt De GGZ kampt met lange wachttijden. Psylaris maakt therapie direct schaalbaar met evidence‑based Virtual‑Reality‑modules. Onze oplossing Psylaris ontwikkelt autonome VR‑therapieën voor EMDR, Exposure en CGT. Cliënten volgen de sessies zelfstandig, thuis of in de praktijk, terwijl de therapeut in real‑time voortgangsdata ontvangt en de regie houdt. Het resultaat: tot 40 % minder behandelminuten per traject én snellere symptoomreductie. Bewezen impact: ● 850+ zorgorganisaties in NL, BE & DE ● 100 000+ VR‑sessies sinds 2021 ● Onafhankelijke studies met universiteiten en GGZ‑instellingen bevestigen onze effectiviteit Onze missie De druk op de GGZ verlichten zonder de menselijke maat te verliezen. Samen met behandelaren maken we zorg schaalbaar, persoonlijk en toekomstbestendig.

Brightlands Venture Partners (BVP) is a venture capital fund manager backing founders who turn breakthrough solutions into lasting impact. We invest in early-stage companies addressing complex, system-level challenges across health, agrifood, and renewable chemistry; sectors that are fundamental to a resilient, future-proof society. We believe the transition toward healthier and more sustainable systems is both a structural necessity and one of the most compelling long-term investment opportunities of our generation. We partner with founders and teams who combine deep domain expertise, strong execution capability, and clear growth ambition. With our current fund, we invest at the Seed to Series A stage, with initial ticket sizes ranging from €250k to €2m, focusing on companies based in Europe. Impact has shaped our investment approach from the very beginning. Long before impact investing became a label, it was part of our DNA. Today, this conviction is embedded across our full investment lifecycle, in line with our SFDR Article 9 classification. We can act as lead investor or co-investor and consistently reserve capital for follow-on rounds, ensuring long-term alignment with our portfolio companies. BVP currently manages four funds with €120 million in committed capital. 📍 Our team is based in the Netherlands, Luxembourg, and Switzerland, and we are active across Europe. 📩 For questions, pitches, or collaborations, email works best: info@bvp.capital

Carol è un servizio di virtual primary care in abbonamento, che permette di accedere a servizi sanitari digitali in modo facile e veloce, sempre e ovunque. Lapp comprende un ecosistema di servizi sanitari che offrono un’esperienza pratica, efficiente e totalmente digitale: teleconsulti di medicina generale via video e chat, prescrizione elettronica di ricette farmaceutiche e specialistiche; acquisto di farmaci con consegna a domicilio; prenotazione di visite specialistiche ed esami diagnostici nelle migliori strutture partner. Carol è il primo provider di servizi di telemedicina in Italia ad essere autorizzato dall’SSN come ambulatorio virtuale di medicina generale in regime privato. Un team di medici interno altamente qualificato e sempre reperibile garantisce una presenza dedicata ed il più elevato standard di qualità ai propri pazienti, supportato da una piattaforma tecnologica moderna.

We are BOI. The AI Transformation Studio. Everyone sells AI efficiencies. We build for growth. For more than 16 years we’ve helped companies innovate and grow with new technology. Today, we help companies rebuild what they sell, how they operate and grow, with AI at the core. We partner with the world’s most ambitious businesses, including Nestlé, ING, Walmart, Coca-Cola, GSK, Siemens, J&J, and Mastercard.

CRB is a Private Venture Capital Management firm specialized in Health Technologies. It was founded by a senior multi-disciplinary executive team. It has incorporated three previous Funds with focus on Biotech (Fund I), Medtech (Fund II), and Digital Health (Fund Nuubo). Currently incorporating the Fund III (CRB Digital Health III), a specialized Fund on Digital Health supported by a team with a large experience in startups, scaleups, corporates, and public health institutions. Based in Madrid and Barcelona, with access to the most innovative hubs in Europe. comunicacion@crossroadbiotech.com